| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/07/2005 | US20050148012 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |
| 07/07/2005 | US20050147665 Consisting of eicosapentaenoic acid or derivative, vitamin B 12, folic acid, at a maximum daily dose of 5 mg, and vitamin B6, at a maximum daily dose of 20 mg, and optionally at least one antioxidant; treatment of psychiatric disorders; schizophrenia, Alzheimer's disease, dementia, Parkinson's disease |
| 07/07/2005 | US20050147649 Method and dietary composition for improving fat digestibility |
| 07/07/2005 | US20050147619 Anion exchange resin adsorbed fraction immunopotentiator and promoter for recovery from loaded stress originating in matsutake mushroom |
| 07/07/2005 | US20050147612 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 07/07/2005 | US20050147601 Angiogenesis inhibitor; wound healing agents; prevent cell adhesion in mallals |
| 07/07/2005 | US20050147591 Methods and compositions for viral enhancement of cell killing |
| 07/07/2005 | US20050147586 Novel therapeutic processes and useful compositions therefor |
| 07/07/2005 | US20050147583 Carbamylation to form a water soluble prodrug that has a biologically active agent linked to a water soluble non-immunogenic polymer; a hydrolyzing through carbamate bond; drug delivery; no enzymes or catalysts needed for release of acitve agent |
| 07/07/2005 | US20050147567 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 07/07/2005 | US20050147563 Imaging lymph nodes with a Gadolinium complex of 10-[2-hydroxy-4-aza-5-oxo-7-aza-7-(perfluorooctylsulfonyl)-nonyl]-1,4,7-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecane; in vivo contrast media in nuclear spin tomography; blood-pool agents, lymphographic agents |
| 07/07/2005 | DE10346950A1 Four-component herbal composition in form of capsules, useful for long-term, pre- or post-operative treatment of malignant tumors |
| 07/07/2005 | CA2688944A1 Humanized anti-ngf antibodies |
| 07/07/2005 | CA2551546A1 Preventive/remedy for cancer |
| 07/07/2005 | CA2551543A1 Method of suppressing cancer |
| 07/07/2005 | CA2551189A1 Therapeutic agents and uses therefor |
| 07/07/2005 | CA2551181A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | CA2550900A1 Methods for detecting markers associated with endometrial disease or phase |
| 07/07/2005 | CA2550843A1 Novel phenylalanine derivatives |
| 07/07/2005 | CA2550839A1 Antharquinone compounds as anti cancer compounds |
| 07/07/2005 | CA2550657A1 Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation |
| 07/07/2005 | CA2550482A1 Vaccine comprising an angiomotin or a polynucleotide encoding an angiomotin and its uses for the treatment of angiogenic-related disorders |
| 07/07/2005 | CA2550298A1 Reduction of toxicity of multi-targeting antifolates |
| 07/07/2005 | CA2549937A1 Human anti-idiotypic antibody fragments that mimic her-2/neu |
| 07/07/2005 | CA2549510A1 Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors |
| 07/07/2005 | CA2548662A1 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
| 07/07/2005 | CA2548108A1 Use of superoxide dismutase mimetics and reductase glutathione in the form of anticancer drugs |
| 07/07/2005 | CA2545696A1 An oncolytic adenovirus |
| 07/07/2005 | CA2544562A1 Bispecific antibodies |
| 07/06/2005 | EP1550720A1 Mutated androgen receptor, cancer cells expressing the same, method of constructing the same and use thereof |
| 07/06/2005 | EP1550719A1 Methods and medicament for inhibition the expression of a defined gene |
| 07/06/2005 | EP1550675A1 Phospholipid derivative |
| 07/06/2005 | EP1550662A1 Novel adenine compound and use thereof |
| 07/06/2005 | EP1550660A1 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/06/2005 | EP1550657A1 Amine compounds and use thereof |
| 07/06/2005 | EP1550459A1 Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use |
| 07/06/2005 | EP1550454A1 Extracorporeal photopheresis in combination with anti-TNF treatment |
| 07/06/2005 | EP1550453A1 Cancer antigen peptide preparation |
| 07/06/2005 | EP1550449A1 Antitumor agents with the use of hsv |
| 07/06/2005 | EP1550444A1 Controlled releases system containing temozolomide |
| 07/06/2005 | EP1549951A2 Semaphorin-like proteins and methods of using same |
| 07/06/2005 | EP1549756A2 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 07/06/2005 | EP1549751A2 Recombinant adenoviral vectors and applications thereof |
| 07/06/2005 | EP1549741A1 Novel endothelial cells, antibodies directed against said cells and use thereof, in particular for screening angiogenesis inhibiting substances |
| 07/06/2005 | EP1549679A1 Fusion protein comprising angiopoietin receptor-binding and a multimerization domain |
| 07/06/2005 | EP1549669A1 Tumor targeting agents and uses thereof |
| 07/06/2005 | EP1549668A1 Tumor targeting agents and uses thereof |
| 07/06/2005 | EP1549667A1 Tumor targeting agents and uses thereof |
| 07/06/2005 | EP1549660A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 07/06/2005 | EP1549651A1 Kinase inhibitors |
| 07/06/2005 | EP1549650A1 Substituted c-imidazo[1,2-a]pyridin-3-yl-methylamines |
| 07/06/2005 | EP1549640A2 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
| 07/06/2005 | EP1549620A1 Indazolecarboxamide derivatives, preparation and use thereof as cdk1, cdk2 and cdk4 inhibitors |
| 07/06/2005 | EP1549618A1 Pyrazolone compounds as thrombopoietin receptor activators |
| 07/06/2005 | EP1549614A2 Vasculostatic agents and methods of use thereof |
| 07/06/2005 | EP1549613A1 Sulfonamides having antiangiogenic and anticancer activity |
| 07/06/2005 | EP1549598A1 Napththalene derivatives which inhibit the cytokine or biological activity of macrophage migration inhibitory factor (mif) |
| 07/06/2005 | EP1549351A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 07/06/2005 | EP1549341A2 Novel tissue factor targeted antibodies as anticoagulants |
| 07/06/2005 | EP1549340A1 Biofunctional cpg or oligo-/polynucleotide and toxin or enterotoxin containing composition |
| 07/06/2005 | EP1549335A1 A method of modulating cellular activity and molecules for use therein |
| 07/06/2005 | EP1549329A1 Extract with anti-tumor and anti-poisonous activity |
| 07/06/2005 | EP1549322A2 Lipid a and other carbohydrate ligand analogs |
| 07/06/2005 | EP1549320A1 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies |
| 07/06/2005 | EP1549319A2 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 07/06/2005 | EP1549316A1 INHIBITORS OF TFG&bgr; |
| 07/06/2005 | EP1549308A1 An inhibitor of the shh signalling pathway and a testosterone supressing agent for the treatment of cancer |
| 07/06/2005 | EP1549301A2 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 07/06/2005 | EP1549291A1 Injection formulation |
| 07/06/2005 | EP1549269A2 Cyclodextrin-based materials, compositions and uses related thereto |
| 07/06/2005 | EP1549156A1 Denatured carob flour (dcf) with a low content of soluble tannins and sugars, meant for human consumption and process to obtain it |
| 07/06/2005 | EP1411938B1 Use of cyclopamine for the manufacture of a medicament for the treatemnt of psoriasis |
| 07/06/2005 | EP1390370A4 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| 07/06/2005 | EP1330254B1 Treatment of cancers by aplidine in conjunction with carnitine or acetylcarnitine |
| 07/06/2005 | EP1315720B1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof |
| 07/06/2005 | EP1307188A4 Cannabinoid drugs |
| 07/06/2005 | EP1280809B1 Antitumoral ecteinascidin derivatives |
| 07/06/2005 | EP1239862B1 Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating tumor diseases |
| 07/06/2005 | EP1230375B1 Inhibiting gene expression with dsrna |
| 07/06/2005 | EP1162982B9 USE OF STABILISED OLIGONUCLEOTIDES FOR PREPARING A MEDICament WITH ANTITUMOUR ACTIVITY |
| 07/06/2005 | EP1140909B1 Novel inhibitors of farnesyl-protein transferase |
| 07/06/2005 | EP1044001B1 Integrin receptor antagonists |
| 07/06/2005 | CN1636069A Method of determining a chemotherapeutic regimen based on ERCCI expression |
| 07/06/2005 | CN1636067A TACIs and BR3 polypeptides and uses thereof |
| 07/06/2005 | CN1636064A Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 07/06/2005 | CN1636061A Novel serine protease genes related to DPPIV |
| 07/06/2005 | CN1636060A Methods of delivery of exogenous proteins to the cytosol and uses thereof |
| 07/06/2005 | CN1636059A Novel method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2 |
| 07/06/2005 | CN1636021A Preparation and use of solidified oils |
| 07/06/2005 | CN1636018A 组织特异性表达 Tissue-specific expression |
| 07/06/2005 | CN1636017A Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
| 07/06/2005 | CN1636014A Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects |
| 07/06/2005 | CN1636006A Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors |
| 07/06/2005 | CN1636005A Benzothiazinone and benzoxazinone compounds |
| 07/06/2005 | CN1636003A Vitamin D3 derivatives and remedies using the same |
| 07/06/2005 | CN1635988A Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/06/2005 | CN1635908A Antibodies that immunospecifically bind to trail receptors |
| 07/06/2005 | CN1635901A Remodeling and glycoconjugation of peptides |
| 07/06/2005 | CN1635896A Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
| 07/06/2005 | CN1635886A Method for treating diseases with omega interferon |